- Home
- ASGI vs RLMD Comparison
ASGI vs RLMD Comparison
Compare ASGI & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASGI | RLMD |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.6M | 784.6M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ASGI | RLMD |
|---|---|---|
| Price | $23.76 | $7.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.40 |
| AVG Volume (30 Days) | 134.4K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $18.53 | $0.27 |
| 52 Week High | $25.95 | $7.94 |
Technical Indicators
Market Signals| Indicator | ASGI | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 55.70 |
| Support Level | $21.81 | $6.81 |
| Resistance Level | $24.59 | $7.41 |
| Average True Range (ATR) | 0.42 | 0.43 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 42.46 | 37.78 |
Price Performance
Historical ComparisonAbout ASGI abrdn Global Infrastructure Income Fund of Beneficial Interest
abrdn Global Infrastructure Income Fund is a non-diversified, closed-end management investment company. Its objective is to seek to provide a high level of total return with an emphasis on current income by investing in assets that provide necessary services to society.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.